• Economy
  • Politics
  • Society
  • Securities
  • Real estate
  • Culture
  • Entertainment
  • Sports
  • Opinion
Economy Corporation Pharma & Bio
Society Politics IT·Science
Securities Real Estate Global
Opinion Entertainment Sports Culture
Video Auto in Golf in
PHARM EDAILY Market in TheBeLT
Economy
Business·Industry

HLB INC.’s New Liver Cancer Drug Receives Third CRL… Delays in Approval Raise Concerns About Commercial Viability

HLB INC.(028300)’s new liver cancer drug, the combination therapy of “Riboceranib and Camrelizumab,” has received its third Complete Response Letter (CRL) from the U.S. Food and Drug Administration (F…
  • 2026-07-13 08:26:01
  • KIM SAE-MI
Business·Industry

Despite the Peptron, Inc. and HLB INC. Shock, the Biotech Sector Remains Bullish… Warm Sentiment Spreads Across KOSDAQ [Biotech Spotlight]

On the 10th, in the biotech sector, Peptron, Inc.(087010)and #HLB INC. all hit their daily price limits due to individual negative factors. Nevertheless, buying momentum spread across the KOSDAQ marke…
  • 2026-07-12 08:10:03
  • KIM SAE-MI
Business·Industry

Micron Bets 375 Trillion Won on the U.S. … Samsung and SK Face Growing Pressure to Invest in the U.S.

As Micron expands its semiconductor investment in the U.S. to $250 billion (approximately 375 trillion won), pressure on SamsungElectronics and SK hynix to invest in the U.S. is expected to intensify.…
  • 2026-07-10 15:35:14
  • JAEMIN SONG
Business·Industry

K-Battery Set to Return to Profitability in Q2… North American ESS Supply Chain Now Complete

Signs of a turnaround for Korean battery companies are becoming increasingly clear in the second half of the year. Having passed through the “EV chasm” (a temporary slowdown in demand), these companie…
  • 2026-07-10 15:08:34
  • SOYEON KIM
Business·Industry

Peptron, Inc. Emphasized "Smooth Sailing" with Lilly, but... Excluded from Joint Research After Mounjaro and MTA

Peptron, Inc.(087010), following its official statement that its joint research with Eli Lilly is proceeding normally, issued a revised notice around 12:00 p.m. today explaining that tirzepatide is in…
  • 2026-07-10 14:01:02
  • KIM SAE-MI
Business·Industry

Samsung TV Plus Expands Musical Content… Exclusively Premieres 'Maybe a Happy Ending'

SamsungElectronics is expanding its musical content offerings through "Samsung TV Plus," its ad-supported free streaming service (FAST). Starting with the original Korean production of "Maybe Happy En…
  • 2026-07-10 08:31:58
  • JAEMIN SONG
Business·Industry

Marine Tourism, Seawater, and the Ministry of Culture, Sports and Tourism Need a 'Joint Project' [Tourism Biz]

Experts point out that to develop marine tourism—which encompasses cruises, marinas, island tourism, fishing village tourism, and water sports—into a new growth engine for the national tourism industr…
  • 2026-07-10 06:00:05
  • Kang Gyeong-rok
Business·Industry

Busan Brand Festa and Seoul GoCaf Start on the 10th… This Week’s Must-See Events

Every Wednesday, “The BeLT,” the tourism and MICE news team of the comprehensive economic daily E-Daily, features the latest developments and diverse industry news from the domestic and international …
  • 2026-07-09 21:31:11
  • LEE SEON-WOO
Business·Industry

[Exclusive] Peptron, Inc.’s Hopes for ‘Once-a-Month Mounjaro’ Shaken; “No Terzepatide in Joint Research with Lilly”

Choi Ho-il, CEO of Peptron, Inc. (Photo: E-Daily DB Inc.) “In our joint research with Company L, we are developing an entirely different peptide formulation together, and Tuzepatide is not include…
  • 2026-07-09 20:56:02
  • KIM SAE-MI
Business·Industry

Micron Forms 'Future In-Vehicle Systems' Alliance with Ford and GM… Pressure on Samsung and SK

U.S.-based Micron has signed long-term supply agreements for automotive memory with U.S. automakers such as Ford and General Motors (GM), positioning itself to secure a leading position in the future …
  • 2026-07-09 15:51:49
  • SOYEON KIM
prev 31 32 33 34 35 36 37 38 39 40 next

PHARM EDAILY

Shorts

EDAILY
  • 92, Tongil-ro, Jung-gu, Seoul, Korea
  • +82 2 3772 0114
  • webmaster@edaily.co.kr

※ This article has been translated using AI technology for the convenience of readers.

EDAILY provides this translation on an “as is” basis and makes no warranties, express or implied, regarding its accuracy, reliability, completeness, merchantability, or fitness for a particular purpose.
Due to the limitations of machine translation, the translated content may differ from the original Korean article. In the event of any discrepancy, the original Korean version shall prevail.
EDAILY shall not be liable for any loss or damage arising from the use of, or reliance on, the translated content.

© 2026 Copyrights by edaily. All Rights Reserved.
Korea
English